[Influence of anitiretroviral therapy on bone tissue metabolism in patients with HIV].
The use of antiretroviral therapy has resulted in reduction in HIV related morbidity and mortality but antiretroviral treatment have been associated with long term toxicities. High prevalence of premature osteopenia, osteoporosis and osteonecrosis have been recently detected in patients infected with HIV. The pathogenesis of this bone disorders is still unclear and probably multifactoral. Earlier studies have implicated specific antiretroviral medications as causative factors in the development of osteopenia. Patients not receiving antiretrovirals also have a higher than expected prevalence of reduced BMD, which suggests that HIV itself may be a contributing factor, mediated by immune activation and cytokines. Improved understanding of the pathogenesis of these bone disorders should result in better prevention and treatment.
Klinika i Katedra Chorób Zakaźnych i Hepatologii CM UMK. a.olczak@wsoz.pl
Anita
A
Olczak
Małgorzata
M
Pawłowska
Wiktor
W
Drózdz
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D001862:Bone Resorption / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D010020:Osteonecrosis / Q000209:etiology; D010024:Osteoporosis / Q000209:etiology; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors